Table 1.
Demographic and obstetrical characteristics of the study population
| Patient Characteristics | Uncomplicated Pregnancy (n=886) | SGA (n=108) | Preeclampsia (n=40) | Stillbirth (n=5) | Other complicatio ns (n=230) |
|---|---|---|---|---|---|
| Maternal age (years) | 26.2±5.9 | 26.5 ±7.1 | 23.6 ±5.4* | 27 ±10 | 28 ±6.5 |
| Tobacco use | 10.5% (93) | 18.50% (20) | 12.50% (5) | 0 | 12.2% (28) |
| Nulliparous | 40.2% (356) | 44.4% (48) | 70%* (28) | 40% (2) | 33.0 (76) |
| Multiparous with previous history of preeclampsia | 2.1% (19) | 0.9% (1) | 7.5%* (3) | 0 | 6.1% (14) |
| Multiparous without previous history of preeclampsia | 57.7% (511) | 54.60% (59) | 22.50%* (9) | 60% (3) | 60.9% (140) |
| Body mass index (Kg/m2) | 24.6 ± 4.2 | 24 ±4.3 | 27.4 ±8 | 22.4 ±1.6 | 27.3 ± 6 |
| GA at venipuncture (weeks) | 32.2 ± 1.1 | 32.2 ±1.1 | 32.2 ±1.2 | 32 ±0.9 | 32.2±1.2 |
| Storage time (years) | 6.8 ±0.7 | 6.8 ±0.8 | 6.9 ±1.1 | 6.6 ±0.6 | 6.8 ±0.7 |
| GA at delivery (weeks) | 39.6 ± 1.1 | 39.4 ±1.1 | 38.48* ±1.6 | 36.5* ±2.3 | 38.6± 1.7 |
| Birthweight (grams) | 3505± 399 | 2710*±230 | 3096* ±550 | 2896±642 | 3366±521 |
| PlGF/sVEGFR-1 MoM (median(IQR)) | 1.00 (0.51–1.83) | 0.53* (0.21–1.22) | 0.21* (0.08–0.50) | 0.08* (0.07–0.1) | 0.73 (0.33–1.27) |
| PlGF/sEng MoM (median(IQR)) | 1.00 (0.56–1.78) | 0.59* (0.26–1.10) | 0.27* (0.11–0.63) | 0.18* (0.1–0.3) | 0.74 (0.35–1.18) |
Value expressed as percent (number), mean ± standard deviation or median (interquartile range- IQR);
*
indicated significant difference (p<0.05) compared to combined ‘other + uncomplicated pregnancy’ categories;
GA= gestational age; SGA= pregnancy with small-for-gestational-age neonate, MoM= Multiples of the Median, PlGF= placental growth factor, sEng = soluble endoglin, sVEGFR-1= soluble vascular endothelial growth factor receptor-1; -Medians were calculated among uncomplicated pregnancies (n=886) by quantile regression
Other complications include spontaneous preterm delivery (3%; n=38), chronic hypertension (2.2%; n=28), gestational hypertension (6.8%; n=86); gestational and pregestational diabetes (4.6%; n=58), placental abruption (0.4%; n=5), cholestasis of pregnancy (0.9%; n=12) and placenta previa (0.2%; n=3)